Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib
Key Highlights
- ➤Merck discontinued nemtabrutinib development across the entire BELLWAVE clinical program
- ➤External Data Monitoring Committee found BELLWAVE-011 benefits may not outweigh risks
- ➤Merck stopped Phase 3 BELLWAVE-011, BELLWAVE-008 and BELLWAVE-010 trials
- ➤Nemtabrutinib was evaluated in CLL, SLL and other hematologic malignancies
Expert Statements
Marjorie Green, Senior vice president and head of global oncology clinical development, Merck Research Laboratories
“Following careful analyses of the data from BELLWAVE-011, the decision has been made to discontinue development of nemtabrutinib across the entire clinical program. We are grateful to all of the patients, caregivers and investigators for their many contributions that made these studies possible.”
Marjorie Green, Senior vice president and head of global oncology clinical development, Merck Research Laboratories
“We continue to pursue solutions for patients with hematologic malignancies and focus on advancing our hematology pipeline to help more patients with blood cancers.”
Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development program evaluating nemtabrutinib (MK-1026), an investigational, oral, non-covalent Bruton's tyrosine kinase (BTK) inhibitor. Nemtabrutinib is being evaluated for patients with chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL) and other hematologic malignancies in the BELLWAVE program.
Get started
Create a free account to read the full story.
